Compare FRST & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | CADL |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.2M | 280.3M |
| IPO Year | 2006 | 2021 |
| Metric | FRST | CADL |
|---|---|---|
| Price | $12.74 | $4.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.71 |
| AVG Volume (30 Days) | 78.5K | ★ 1.4M |
| Earning Date | 04-28-2026 | 03-12-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 477.27 | 58.62 |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.54 | N/A |
| P/E Ratio | $5.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $4.25 |
| 52 Week High | $14.55 | $8.69 |
| Indicator | FRST | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 43.79 |
| Support Level | $12.48 | $4.57 |
| Resistance Level | $14.42 | $5.42 |
| Average True Range (ATR) | 0.36 | 0.25 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 22.52 | 44.44 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.